Evidence map›Paper›PMID 41734646›Full record

ReviewCurrent opinion in chemical biology2026

DVD-IgG1 antibody-drug conjugates: Expanding the landscape of targeted cancer therapy.

Alexander F Kiefer, Andrew D Steele, Christoph Rader, Ben Shen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexander F KieferDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, United States.
Andrew D SteeleDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, United States; Natural Products Discovery Center, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida Jupiter, Florida 33458, United States.
Christoph RaderDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, United States; Skaggs Graduate School of Chemical and Biological Sciences, Scripps Research, Jupiter, FL 33458, United States.
Ben ShenDepartment of Chemistry, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, United States; Natural Products Discovery Center, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida Jupiter, Florida 33458, United States; Skaggs Graduate School of Chemical and Biological Sciences, Scripps Research, Jupiter, FL 33458, United States; Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL 33458, United States. Electronic address: shenb@scripps.edu.

Funding

Mining Actinomycetal Genomes for Natural Product Discovery and BiosynthesisR35GM134954 · NIGMS · UNIVERSITY OF FLORIDA · PI Ben Shen · 2020 to 2026
$5.1M
Novel Enediyne-Based Antibody-Drug Conjugates for CancersR01CA204484 · NCI · UNIVERSITY OF FLORIDA · PI Natarajan Muthusamy, Ben Shen · 2017 to 2026
$4.6M
Biosynthesis of the Leinamycin Family of Natural Products: Mechanistic Studies and Chemoenzymatic Analog SynthesisF32GM133114 · NIGMS · UNIVERSITY OF FLORIDA · PI STEELE, ANDREW · 2019 to 2021
$195k
NCI NIH HHS R01 CA204484NIGMS NIH HHS F32 GM133114NIGMS NIH HHS R35 GM134954
6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, yet conventional IgG-based formats are often limited by stochastic conjugation, yielding heterogeneous ADCs. Dual-variable domain IgG1 (DVD-IgG1) antibodies offer a modular solution by enabling precise, site-specific conjugation through the catalytic lysine and engineered arginine or cysteine residues, affording homogeneous ADCs. This review summarizes recent advances in DVD-IgG1-based ADCs, highlighting site-specific conjugation, compatibility with diverse linker chemistries, and incorporation of both established and experimental payloads. Together, these developments position DVD-IgG1s as a versatile platform to expand the chemical and biological design space of next-generation ADCs.

Indexed as

Antineoplastic AgentsImmunoconjugatesImmunoglobulin GNeoplasmsAnimalsHumansAntineoplastic AgentsImmunoconjugatesImmunoglobulin G

Identifiers

PMID41734646
PMCPMC13419680

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.